StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Contract Liability Roll-Forward: Revenue Recognized by Year

Contract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M) ($M)

Natera Contract Liability Roll-Forward: Revenue Recognized: -$19.2M in FY2025, up 40.2% from a year earlier.

Latest, FY2025
-19.2
Period ended Dec 31, 2025
Change on a year earlier
+40.2%
-13.7 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (2026-02-27) ↗

Reported in Form 10-K/10-Q Note — Contract Liabilities Roll-Forward (XBRL).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedContract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M) ($M)Year on yearSource
FY2025Dec 31, 2025-19.2+40.2%Form 10-K (2026-02-27) ↗
FY2024Dec 31, 2024-13.7+29.6%Form 10-K (2026-02-27) ↗
FY2023Dec 31, 2023-10.6+20.3%Form 10-K (2025-02-28) ↗
FY2022Dec 31, 2022-8.78-76.8%Form 10-K (2024-02-29) ↗
FY2021Dec 31, 2021-37.8+421.1%Form 10-K (2023-03-01) ↗
FY2020Dec 31, 2020-7.25+625.0%Form 10-K (2021-02-26) ↗
FY2019Dec 31, 2019-1+40.8%Form 10-K (2020-03-02) ↗
FY2018Dec 31, 2018-0.71–Form 10-K (2019-03-15) ↗

Cite this data

StockData. (2026). Natera Contract Liability Roll-Forward: Revenue Recognized ($M), annual FY2018–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-rev-from-beg-balance

See every metric in the Natera KPI table. Data updated Nov 2, 2026.